Board of Directors

Kuur Therapeutics has an active and engaged board of directors with extensive experience in the pharma and biotech industries.

The Team

Board of Directors

Dr Annalisa Jenkins
Chair of the Board of Directors
Dr Annalisa Jenkins

Annalisa Jenkins, MBBS, FRCP, joined the Board of Directors as Chairperson in December 2017. Prior to joining Kuur Therapeutics, Dr. Jenkins served as President and CEO of Dimension Therapeutics and held multiple leadership positions, including Executive Vice President, Head of Global Research and Development for Merck Serono, where she led global medical affairs and quality and was a member the Pharmaceutical Executive Committee.

Prior to this, Dr. Jenkins had a successful 14-year career at Bristol-Myers Squibb (BMS), attaining the role of Senior Vice President and Head of Global Medical Affairs. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital, University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service. Dr. Jenkins is a board member of several growing companies and a member of the Science Board to the U.S. Food & Drug Administration (FDA).  She also Chairs the Court at the London School of Hygiene and Tropical Medicine.

Back
View Profile
Shawn Davis
Non-Executive Director
Shawn Davis
Back
View Profile
Julia P. Gregory
Non-Executive Director
Julia P. Gregory

Julia P. Gregory, Chair and CEO of Isometry Advisors, Inc., a biotechnology financial and management advisory firm, has 16 years of executive management experience and 20 years of investment banking experience. As an executive, she successfully raised more than $1.5 billion for her companies through initial public offerings, public and private offerings and creative strategic alliances including GlaxoSmithKline, BristolMyers Squibb, Takeda Pharmaceuticals, Genentech, (Roche) and Human Genome Sciences (GSK), among others.

She was formerly CEO of the novel anti-infectives company, ContraFect Corporation, CEO of FivePrime Therapeutics, an immuno-oncology company, and EVP, Head of Corporate Development and CFO of Lexicon Pharmaceuticals where she lead the Company’s $220 million IPO. She is currently on the board of directors of public companies, IMV Inc, the Sosei Group and Biohaven Pharmaceutical Holding Company Ltd and multiple private biotech company boards. Ms. Gregory attained a Masters of Business Administration from the Wharton School at the University of Pennsylvania, and earned her B.A. at the George Washington University.

Back
View Profile
Dr Thomas Hecht
Non-Executive Director
Dr Thomas Hecht

Thomas has been on the Kuur Therapeutics Board since 2012 and he was Chairman until December 2017. He was previously Vice President Marketing at Amgen Europe, Lucerne, Switzerland. Following his academic career, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, he served as Co-Head of the Program for Bone Marrow Transplantation, University of Freiburg, Germany.

Back
View Profile
Dr Sam Williams
Non-Executive Director
Dr Sam Williams

Sam is Managing Partner of the Life Sciences division at IP Group plc. He has over 20 years’ experience in the biotech sector, both as a top-ranked equity analyst in the City of London and, subsequently, as a chief executive and non-executive director. He currently serves as Executive Chairman of Istesso Ltd and as a non-executive director of Microbiotica Ltd, IESO Digital Health and Diurnal Group plc. Sam has a PhD in molecular biology from Cambridge and a degree in biology from Oxford. 

Back
View Profile
Kevin S. Boyle, Sr.
Chief Executive Officer
Kevin S. Boyle, Sr.

Kevin S. Boyle, Sr. is Chief Executive Officer of Kuur Therapeutics, a position he has held since January 2020. He joined Kuur in 2018 as the company’s Chief Financial Officer. Kevin has over 20 years of experience helping companies define and execute strategy and increase shareholder value. He has broad international experience with both public and private companies and has raised over $2.0 billion in capital over his career.

Before joining Kuur Therapeutics, Kevin served as Chief Financial Officer of FloWorks International and had held previous senior finance roles at Sigma Cubed, RecoverCare and SPT.  Kevin graduated from Carnegie Mellon University with a B.S. in Industrial Management, and earned his J.D. from the University of Pennsylvania. He is active in the Houston community, serving as Treasurer of The Center for Hearing and Speech.

Back
View Profile